HK1052182B - 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑 - Google Patents

作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑

Info

Publication number
HK1052182B
HK1052182B HK03104439.8A HK03104439A HK1052182B HK 1052182 B HK1052182 B HK 1052182B HK 03104439 A HK03104439 A HK 03104439A HK 1052182 B HK1052182 B HK 1052182B
Authority
HK
Hong Kong
Prior art keywords
agonists
antagonists
substituted imidazoles
dual histamine
histamine
Prior art date
Application number
HK03104439.8A
Other languages
English (en)
Other versions
HK1052182A1 (en
Inventor
Shih Neng-Yang
G Aslanian Robert
M Solomon Daniel
B Rosenblum Stuart
Wa Mutahi Mwangi
C Tom Wing
D Mc Cormick Kevin
J Piwinski John
Wolin Ronald
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1052182A1 publication Critical patent/HK1052182A1/xx
Publication of HK1052182B publication Critical patent/HK1052182B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03104439.8A 2000-09-20 2003-06-20 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑 HK1052182B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23403900P 2000-09-20 2000-09-20
PCT/US2001/029062 WO2002044141A2 (en) 2000-09-20 2001-09-18 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists

Publications (2)

Publication Number Publication Date
HK1052182A1 HK1052182A1 (en) 2003-09-05
HK1052182B true HK1052182B (zh) 2005-04-01

Family

ID=22879625

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104439.8A HK1052182B (zh) 2000-09-20 2003-06-20 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑

Country Status (14)

Country Link
US (1) US6762186B2 (zh)
EP (1) EP1318996B1 (zh)
JP (1) JP2004514709A (zh)
CN (1) CN1461304A (zh)
AR (1) AR032894A1 (zh)
AT (1) ATE283853T1 (zh)
AU (1) AU2002241459A1 (zh)
CA (1) CA2422729A1 (zh)
DE (1) DE60107586T2 (zh)
ES (1) ES2233708T3 (zh)
HK (1) HK1052182B (zh)
MX (1) MXPA03002446A (zh)
TW (1) TWI228127B (zh)
WO (1) WO2002044141A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003268117A1 (en) * 2002-09-18 2004-04-08 Eli Lilly And Company Histamine h3 receptor antagonists, preparaton and therapeutic uses
US8063650B2 (en) 2002-11-27 2011-11-22 Rambus Inc. Testing fuse configurations in semiconductor devices
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
US7560589B2 (en) 2003-07-28 2009-07-14 Smithkline Beecham Corporation Cycloalkylidene compounds as modulators of estrogen receptor
TWI290140B (en) * 2003-08-25 2007-11-21 Schering Corp 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders
WO2007018459A1 (en) * 2005-08-08 2007-02-15 Astrazeneca Ab Therapeutic agents
US20100029681A1 (en) * 2006-05-26 2010-02-04 Hassan Pajouhesh Heterocyclic compounds as calcium channel blockers
BRPI0720564A2 (pt) 2006-12-22 2011-08-16 Avexa Ltd pirimidinonas biciclìcas e seus usos
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN110878069A (zh) * 2019-12-09 2020-03-13 南京杰运医药科技有限公司 一种4-吗琳基-2-乙基哌嗪的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) * 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
US4829065A (en) * 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
ATE120461T1 (de) * 1990-01-15 1995-04-15 Heumann Pharma Gmbh & Co Imidazolylpropylguanidinderivat, verfahren zu seiner herstellung und diese verbindung enthaltende arzneimittel.
ATE109979T1 (de) 1990-03-30 1994-09-15 Heumann Pharma Gmbh & Co Verwendung von guanidinderivaten zur herstellung eines arzneimittels mit npy-antagonistischer wirkung.
FR2665160A1 (fr) * 1990-07-26 1992-01-31 Esteve Labor Dr Nouveaux derives de 1-diphenylmethylpiperazine, leur preparation et leur application en tant que medicaments.
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
WO1993012093A1 (en) 1991-12-18 1993-06-24 Schering Corporation Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
HU213104B (en) * 1992-06-17 1997-02-28 Richter Gedeon Vegyeszet Process for producing 4-methyl-2-imidazolinone derivatives and pharmaceutical compositions containing them
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
ATE214604T1 (de) 1997-06-24 2002-04-15 Novo Nordisk As Verwendung von somatostatin agonisten und antagonisten zur behandlung von augenkrankheiten
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6133291A (en) * 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists

Also Published As

Publication number Publication date
CA2422729A1 (en) 2002-06-06
EP1318996B1 (en) 2004-12-01
HK1052182A1 (en) 2003-09-05
WO2002044141A3 (en) 2002-11-07
AR032894A1 (es) 2003-12-03
EP1318996A2 (en) 2003-06-18
US20020082278A1 (en) 2002-06-27
DE60107586T2 (de) 2005-10-06
MXPA03002446A (es) 2003-06-19
WO2002044141A2 (en) 2002-06-06
TWI228127B (en) 2005-02-21
ATE283853T1 (de) 2004-12-15
ES2233708T3 (es) 2005-06-16
US6762186B2 (en) 2004-07-13
JP2004514709A (ja) 2004-05-20
AU2002241459A1 (en) 2002-06-11
DE60107586D1 (de) 2005-01-05
CN1461304A (zh) 2003-12-10

Similar Documents

Publication Publication Date Title
EP1206262A4 (en) Y NEUROPEPTID ANTAGONISTS: SPIROISOQUINOLINONE DERIVATIVES
PL366233A1 (en) Substituted pyridoindoles as serotonin agonists and antagonists
ZA200107917B (en) Bicyclic heteroaromatic compounds useful as LH agonists.
IL150632A0 (en) Corticotropin releasing factor antagonists
PL376477A1 (en) Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
IL154604A0 (en) Guanidinobenzamides as mc4-r agonists
PL359619A1 (en) Glucagon antagonists/inverse agonists
PL372295A1 (en) Quinoline derivatives as npy antagonists
MXPA03006484A (es) Derivados de imidazolilo como inhibidores del factor de liberacion de corticotropina.
AU2002223501A1 (en) Glucagon antagonists/inverse agonists
AU2002223500A1 (en) Glucagon antagonists/inverse agonists
HUP0401756A3 (en) Substituted benzimidazole compounds and their use
GB0015562D0 (en) Heterocycles
HK1052182B (zh) 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑
HK1052179A1 (zh) 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑
EP0986553A4 (en) DIHYDROPYRIMIDONE DERIVATIVES AS NPY ANTAGONISTS
HK1052181A1 (zh) 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑
HK1052180A1 (zh) 作為雙重組胺h1和h3激動劑或拮抗劑的取代咪唑
AU7635401A (en) Hetaryl-substituted heterocycles
SI1261588T1 (en) IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS
GB0101223D0 (en) Histamine receptor antagonists
EP1202738A4 (en) DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS
AU6043500A (en) New npy antagonists
GB9927761D0 (en) Anti-microbial compounds and feed additives incorporating the same
GB0009125D0 (en) Antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080918